

CNS SPECTRUMS®

The International Journal of Neuropsychiatric Medicine

ACADEMIC SUPPLEMENT

Assessing Current Practice in Alzheimer's Disease

Introduction

J.E. Mintzer

What Is the Rationale for New Treatment Studies in Alzheimer's Disease?

M.A. Rogawski

What Are the Challenges Faced by Psychiatrists in the Management of Alzheimer's Disease?

J.E. Mintzer

A Guide to Diagnosis of Alzheimer's Disease

M. Sano


What Does Imaging Add to the Management of Alzheimer's Disease?

G.W. Small

Understanding the Latest Advances in Pharmacologic Interventions for Alzheimer's Disease

C.H. van Dyck

This supplement is sponsored by the
American Association for Geriatric Psychiatry



This supplement is supported by an unrestricted
educational grant from



Executive Editor

Jacobo E. Mintzer, MD

Associate Editors

Michael A. Rogawski, MD, PhD

Mary Sano, PhD

Gary W. Small, MD

Christopher H. van Dyck, MD

Faculty Affiliations and Disclosures

Dr. Mintzer is professor of psychiatry, neurology, physiology, and neuroscience at the Medical University of South Carolina in Charleston. He is a consultant to Abbott, AstraZeneca, Eli Lilly, Bristol-Myers Squibb, Capital Research Company, The Council on Healthcare Advisors, Forest, and UCB Pharma; is on the speaker's bureaus for Abbott, AstraZeneca, Eisai America, Eli Lilly, Janssen, and Pfizer; and receives grants and research support from Abbott, the Alzheimer's Disease Cooperative Study, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai America, Eli Lilly, Forest, Fujisawa Institute of America, GlaxoSmithKline, Janssen, Johnson & Johnson, Mitsubishi, the National Institute on Aging, the National Institute of Mental Health, Novartis, Parke-Davis, Pfizer, Sanofi-Synthelabo, Somerset, and Wyeth.

Dr. Rogawski is chief of the Epilepsy Research Section at the National Institute of Neurologic Disorders and Stroke, National Institutes of Health, in Bethesda, Maryland. He is a consultant to Forest Research Institute.

Dr. Sano is professor of psychiatry in the Department of Psychiatry at Mount Sinai School of Medicine in New York City, and director of research at Bronx Veterans Administration Hospital in Bronx, New York. She is a consultant to Forest, Janssen, and Pfizer.

Dr. Small is professor of psychiatric and biobehavioral sciences and director of the UCLA Center on Aging at the University of California, Los Angeles. He is a consultant to Abbott, Amersham, AstraZeneca, CTI Molecular Imaging, Dakim, Eisai, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Merck, MFI, Novartis, Organon, PET/NeT, Pfizer, and Roche.

Dr. van Dyck is associate professor of psychiatry and neurobiology, and director of the Alzheimer's Disease Research Unit at Yale University School of Medicine in New Haven, Connecticut. He is a consultant to Forest; serves on a speaker's bureaus for Forest; and receives grant support from Forest, Janssen, and Pfizer.

Continuing Medical Education Credit

The American Association for Geriatric Psychiatry (AAGP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The AAGP designates this educational activity for a maximum of 2 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity.

Target Audience

Physicians who are interested in emerging treatment strategies for patients with moderate to severe Alzheimer's disease (AD) and appropriate pharmacologic interventions that can favorably impact the quality of life for the patient and the caregiver.

Learning Objectives

After reading this supplement, participants will be better able to:

- Evaluate practical approaches that can assist with detection and diagnosis of AD
- Critically analyze advances in brain imaging and what these techniques add to the management of AD
- Review the rationale for emerging pharmacologic treatment strategies for AD
- Discuss the latest advances in pharmacologic and nonpharmacologic treatment interventions for AD and how these should be best applied to daily clinical practice

Disclaimer

This academic supplement is supported by an unrestricted educational grant from Forest Laboratories. Sponsorship of this review does not imply the sponsor's agreement with the views expressed herein.

Although every effort has been made to ensure that drug doses and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician. Neither the publisher, the sponsor, nor the authors can be held responsible for errors or for any consequences arising from the use of information contained herein. Readers are strongly urged to consult any relevant primary literature. No claims or endorsements are made for any drug or compound currently under clinical investigation.

Copyright ©2004 by MBL Communications, Inc.

333 Hudson St., 7th Floor, New York, NY 10013.

Printed in the USA. All rights reserved, including the right of reproduction, in whole or in part, in any form.

CNS SPECTRUMS®

The International Journal of Neuropsychiatric Medicine

EDITOR

Jack M. Gorman, MD
Mount Sinai School of Medicine
New York, NY

ASSOCIATE AND FOUNDING EDITOR

Eric Hollander, MD
Mount Sinai School of Medicine
New York, NY

INTERNATIONAL EDITOR

Joseph Zohar, MD
Chaim Sheba Medical Center
Tel-Hashomer, Israel

ASSOCIATE INTERNATIONAL EDITORS

EUROPE

Donatella Marazziti, MD
University of Pisa
Pisa, Italy

MID-ATLANTIC

Dan J. Stein, MD, PhD
University of Stellenbosch
Tygerberg, South Africa

FAR EAST

Shigeto Yamawaki, MD, PhD
Hiroshima University School
of Medicine
Hiroshima, Japan

CONTRIBUTING WRITERS

Jacobo E. Mintzer, MD
Michael A. Rogawski, MD, PhD
Mary Sano, PhD
Gary W. Small, MD
Christopher H. van Dyck, MD

MEDICAL REVIEWER

David L. Ginsberg, MD

BOARD OF ADVISORS

NEUROLOGISTS

Mitchell F. Brin, MD
University of California, Irvine
Irvine, CA
Jeffrey L. Cummings, MD
University of California, Los Angeles
Los Angeles, CA
Jerome Engel, Jr., MD, PhD
University of California, Los Angeles
Los Angeles, CA
Mark S. George, MD
Medical University of South Carolina
Charleston, SC
Deborah Hirtz, MD
National Institute of Neurological
Disorders and Stroke, NIH
Rockville, MD
Richard B. Lipton, MD
Albert Einstein College of Medicine
Bronx, NY
C. Warren Olanow, MD, FRCPC
Mount Sinai School of Medicine
New York, NY
Steven George Pavlakis, MD
Maimonides Medical Center
Brooklyn, NY
Stephen D. Silberstein, MD, FACP
Thomas Jefferson University
Philadelphia, PA
Michael Trimble, MD, FRCP, FRPsych
National Hospital for Neurology
and Neurosurgery
London, United Kingdom

PSYCHIATRISTS

Margaret Altemus, MD
Cornell University Medical College
New York, NY
Dennis S. Charney, MD
National Institute of Mental Health
Bethesda, MD
Dwight L. Evans, MD
University of Pennsylvania
Philadelphia, PA
Siegfried Kasper, MD
University of Vienna
Vienna, Austria
Martin B. Keller, MD
Brown Medical School
Providence, RI
Lorrin M. Koran, MD
Stanford University School of Medicine
Stanford, CA
Yves Lecrubier, MD
Hôpital de la Salpêtrière
Paris, France
Herbert Y. Meltzer, MD
Vanderbilt University Medical Center
Nashville, TN
Stuart A. Montgomery, MD
St. Mary's Hospital Medical School
London, United Kingdom
Charles B. Nemeroff, MD, PhD
Emory University School of Medicine
Atlanta, GA
Humberto Nicolini, MD, PhD
National Mexican Institute of Psychiatry
Mexico City, Mexico
Stefano Pallanti, MD, PhD
University of Florence
Florence, Italy
Katharine Phillips, MD
Brown Medical School
Providence, RI
Harold A. Pincus, MD
Western Psychiatric Institute & Clinic
RAND-University of Pittsburgh Health
Institute, Pittsburgh, PA
Scott L. Rauch, MD
Massachusetts General Hospital
Charlestown, MA
Alan F. Schatzberg, MD
Stanford University School of Medicine
Stanford, CA
Thomas E. Schlaepfer, MD
University of Bonn
Bonn, Germany
Stephen M. Stahl, MD, PhD
University of California, San Diego
La Jolla, CA
Norman Sussman, MD, DFAPA
New York University Medical School
New York, NY
Karen Dineen Wagner, MD, PhD
The University of Texas Medical Branch
Galveston, Texas
Herman G.M. Westenberg, MD
University Hospital Utrecht
Utrecht, The Netherlands
Stuart C. Yudofsky, MD
Baylor College of Medicine
Houston, TX

MBL COMMUNICATIONS Corporate Staff

CEO & PUBLISHER

Darren L. Brodeur

ASSOCIATE PUBLISHER

Elizabeth Katz

MANAGING EDITOR

Christopher Naccari

SENIOR EDITOR

Deborah Hughes

DEPUTY SENIOR EDITOR

José R. Ralat

ACQUISITIONS EDITORS

Lisa Arrington

Shoshana Bauminger

ASSISTANT EDITOR

Emil J. Ross

PUBLISHING ASSOCIATE

Shelley Wong

ART DIRECTOR

Derek Oscarson

CONTROLLER

John Spano

NATIONAL ACCOUNT MANAGER

Kelly J. Staley

INFORMATION TECHNOLOGY

Clint Bagwell Consulting

OFFICE ASSISTANT

Manuel Pavón

CORPORATION COUNSEL

Lawrence Ross, Esq.

Bressler, Amery, and Ross

CNS SPECTRUMS®

The International Journal of Neuropsychiatric Medicine

Table of Contents

July 2004

Volume 9 – Number 7 – Supplement 5

Based on Proceedings From the 17th Annual Meeting of the American Association for Geriatric Psychiatry, held February 21-24, 2004, in Baltimore, Maryland

- 5 Introduction: Assessing Current Practice in Alzheimer's Disease**
By Jacobo E. Mintzer, MD
- 6 What Is the Rationale for New Treatment Studies in Alzheimer's Disease?**
By Michael A. Rogawski, MD, PhD
- 13 What Are the Challenges Faced by Psychiatrists in the Management of Alzheimer's Disease?**
By Jacobo E. Mintzer, MD
- 16 A Guide to Diagnosis of Alzheimer's Disease**
By Mary Sano, PhD
- 20 What Does Imaging Add to the Management of Alzheimer's Disease?**
By Gary W. Small, MD
- 24 Understanding the Latest Advances in Pharmacologic Interventions for Alzheimer's Disease**
By Christopher H. van Dyck, MD
- CONTINUING MEDICAL EDUCATION**
- 29 CME quiz accredited by the American Association for Geriatric Psychiatry for 2.0 category 1 credits toward the AMA Physician's Recognition Award.**

Founded in 1996, *CNS Spectrums* is an *Index Medicus* journal and is available on MEDLINE under the citation *CNS Spectr.* It is available online at www.cnsspectrums.com.

CNS Spectrums (ISSN 1092-8529) is published monthly by MBL Communications, Inc. 333 Hudson Street, 7th Floor, New York, NY 10013.

One-year subscription rates: domestic \$120; foreign \$185; in-training \$75. For subscriptions: Phone: 212-328-0800; Fax: 212-328-0600; Web: www.cnsspectrums.com.

Postmaster: Send address changes to *CNS Spectrums* c/o PPS Medical Marketing Group 264 Passaic Avenue, Fairfield, NJ 07004-2595.

For editorial inquiries, please fax us at 212-328-0600 or e-mail us at dh@mblcommunications.com. For bulk reprint purchases, please contact: Kelly J. Staley at kjs@mblcommunications.com.

Opinions and views expressed by authors are their own and do not necessarily reflect the views of the publisher, MBL Communications, Inc., or the editorial advisory board. Advertisements in *CNS Spectrums* are accepted on the basis of adherence to ethical medical standards, but acceptance does not imply endorsement by *CNS Spectrums* or the publisher.

CNS Spectrums is a registered trademark of CNS Spectrums, LLC, New York, NY. Permission to reproduce articles in whole or part must be obtained in writing from the publisher. Audit Bureau of Circulations member.

MBL
communications

Copyright ©2004 by MBL Communications, Inc. All rights reserved. Printed in the United States.

CNS SPECTRUMS ONLINE

CNS Spectrums' editorial mission is to address relevant neuropsychiatric topics, including the prevalence of comorbid diseases among patients, and original research and reports that emphasize the profound diagnostic and physiologic connections made within the neurologic and psychiatric fields. The journal's goal is to serve as a resource to psychiatrists and neurologists seeking to understand and treat disturbances of cognition, emotion, and behavior as a direct consequence of central nervous system disease, illness, or trauma.